All News

A roundup of the latest news and updates for patients with prostate cancer from CURE®.

The Food and Drug Administration approves Gavreto for treatment of patients with metastatic, RET fusion-positive non-small cell lung cancer.

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

From researchers identifying honeybee venom’s potential to kill cancer cells in a lab to a new study showing cancer risk was not significantly associated with use of permanent hair dye in women, here’s what’s happening in the cancer landscape this week.

The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.

Allogeneic hematopoietic stem cell transplant’s role in the chronic lymphocytic leukemia has changed due to new novel agents, but research shows its still effective despite novel agent exposure.

Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.

Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.

An early phase 1b/2 study of Copiktra in combination of standard of care shows how the treatment is active for patients with chronic lymphocytic leukemia but further study is needed to ensure it is an effective and safe alternative to standard of care.

“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an effective, safe, and ideally outpatient regimen for MCL,” the authors wrote.

The approval for patients with acute myeloid leukemia was based on data from the phase 3 QUAZAR AML-001 trial, which demonstrated that patients who received Onureg achieved a median overall survival of 24.7 months compared to 14.8 months for those who received placebo.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for August 2020.

On social media, CURE® recently asked its readers what their thoughts were on the medical use of cannabis. Here, we share some of their responses.

A roundup of the latest news and updates for patients with acute myeloid leukemia from CURE®.

CURE® compiled a roundup of five recent reports patients with lymphoma may have missed.

Arzerra will be available at no cost to patients via an oncology patient access program which will be facilitated through Patient Access Novartis Oncology.

Chadwick Boseman, known best for his role in “Black Panther,” has died after receiving a colon cancer diagnosis four years ago.

Eryaspase, a novel drug candidate, is being evaluated in patients with second-line metastatic pancreatic cancer and those with metastatic triple-negative breast cancer.

Nearly half (48%) of the patients reported experiencing significant fatigue following their surgery. Thirty-nine percent of the patients still reported significant fatigue one year following their surgery.

From Washington Football Team head coach Ron Rivera announcing he has cancer but plans to continue coaching this season, to ”Dancing With the Stars” judge Len Goodman revealing he had surgery to remove skin cancer from his face, here’s what’s happening in the cancer landscape this week.

In addition to improving progression-free survival, researchers have found single-agent Ninlaro (ixazomib) to be a tolerable option in patients with newly diagnosed multiple myeloma who have also already undergone an autologous stem cell transplant.

The novel next-generation ALK tyrosine kinase inhibitor improved survival, compared with Xalkori, in patients with ALK-positive non-small cell lung cancer, potentially representing a new option in the first-line setting.

I am not pining for the end of the pandemic, which makes me a bit of a weirdo among people I know, even though the end of the pandemic would be wonderful. I have been changed as a result of my cancer diagnosis, for it taught me that things can change at any moment.

The test was also approved as a companion diagnostic test to determine which select patients with metastatic castration-resistant prostate cancer could benefit from Rubraca, as well as for three frontline TKIs in patients with non-small cell lung cancer.